Chronic Inflammatory Demyelinating Polyneuropathy Induced by Immune Checkpoint Inhibitors: Case Reports
- 作者: Tikhonova O.1, Druzhinin D.2, Druzhinina E.3, Rukosueva M.1
-
隶属关系:
- Immanuel Kant Baltic Federal University
- Yaroslavl State Medical University
- Pirogov Russian National Research Medical University
- 期: 卷 18, 编号 1 (2024)
- 页面: 98-104
- 栏目: Clinical analysis
- URL: https://journals.rcsi.science/2075-5473/article/view/255210
- DOI: https://doi.org/10.54101/ACEN.2024.1.11
- ID: 255210
如何引用文章
详细
Neurological immune-related adverse events (irAE) are rare but potentially fatal complications associated with the use of immune checkpoint inhibitors (ICI). Recently, there has been a trend towards an increase in the incidence of these cases.
We present two case reports of demyelinating polyneuropathy in patients with skin melanoma treated with pembrolizumab or nivolumab. Unawareness of neurological irAE induced by ICI leads to delayed diagnosis and medical treatment, and this may result in persistent neurological deficit or even patients’ death. Neurological irAEs include myasthenia gravis, aseptic meningitis, encephalitis, myelitis, inflammatory demyelinating neuropathy, myositis or their combinations, etc. Considering their variability in patients treated with ICI and poor representation in publications, each case report can be of practical value.
作者简介
Olga Tikhonova
Immanuel Kant Baltic Federal University
编辑信件的主要联系方式.
Email: offelia78@mail.ru
ORCID iD: 0000-0002-1796-0193
neurologist, functional diagnostics doctor, postgraduate student, assistant Department of Psychiatry and Neurosciences
俄罗斯联邦, KaliningradDmitry Druzhinin
Yaroslavl State Medical University
Email: offelia78@mail.ru
ORCID iD: 0000-0002-6244-0867
D. Sci. (Med.), assistant, Department of nervous diseases with medical genetics and neurosurgery
俄罗斯联邦, YaroslavlEvgenia Druzhinina
Pirogov Russian National Research Medical University
Email: offelia78@mail.ru
ORCID iD: 0000-0002-1004-992X
Cand. Sci. (Med.), Associate Professor, Department of neurology neurosurgery and medical genetics department named after academician L.O. Badalian, Faculty of pediatrics
俄罗斯联邦, MoscowMaria Rukosueva
Immanuel Kant Baltic Federal University
Email: offelia78@mail.ru
ORCID iD: 0009-0003-5610-1839
clinical postgraduate student, Department of psychiatry and neurosciences
俄罗斯联邦, Kaliningrad参考
- Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 2020;11(1):3801. doi: 10.1038/s41467-020-17670-y
- Twomey J.D., Zhang B. Cancer Immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23(2):39. doi: 10.1208/s12248-021-00574-0
- Cuzzubbo S., Javeri F., Tissier M. et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur. J. Cancer. 2017;73:1–8. doi: 10.1016/j.ejca.2016.12.001
- Sharma P., Allison J.P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–214. doi: 10.1016/j.cell.2015.03.030
- Xu M., Nie Y., Yang Y. et al . Risk of neurological toxicities following the use of different immune checkpoint inhibitor regimens in solid tumors: a systematic review and meta-analysis. Neurologist. 2019;24(3):75–83. doi: 10.1097/NRL.0000000000000230
- Johnson D.B., Manouchehri A., Haugh A.M. et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J. Immunother. Cancer. 2019;7(1):134. doi: 10.1186/s40425-019-0617-x
- Van den Bergh P.Y.K., van Doorn P.A., Hadden R.D.M. et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J. Peripher. Nerv. Syst. 2021;26(3):242–268. doi: 10.1111/jns.12455
- Супонева Н.А., Арестова А.С., Мельник Е.А. и др. Валидация шкалы суммарной оценки мышечной силы (MRC sum score) для использования у русскоязычных пациентов с хронической воспалительной демиелинизирующей полинейропатией. Нервно-мышечные болезни. 2023;13(1):68–74. Suponeva N.A., Arestova А.S., Melnik Е.А. et al. Validation of the Medical Research Council sum score (MRCss) for use in Russian-speaking patients with chronic inflammatory demyelinating polyneuropathy. Neuromuscular Diseases. 2023;13(1):68–74. doi: 10.17650/2222-8721-2023-13-1-68-74
- Khan E., Shrestha A.K., Elkhooly M. et al. CNS and PNS manifestation in immune checkpoint inhibitors: a systematic review. J. Neurol. Sci. 2022;432:120089. doi: 10.1016/j.jns.2021.120089
- Johansen A., Christensen S.J., Scheie D. et al.. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review. Neurology. 2019;92(14):663–674. doi: 10.1212/WNL.0000000000007235
- Puwanant A., Isfort M., Lacomis D. et al. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. Neuromuscul. Disord. 2019;29(2):127–133. doi: 10.1016/j.nmd.2018.11.012
- Ruggiero R., Balzano N., Di Napoli R. et al. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years. Front. Immunol. 2023;14:1134436. doi: 10.3389/fimmu.2023.1134436
- Van Raamsdonk C.D., Deo M. Links between Schwann cells and melanocytes in development and disease. Pigment Cell Melanoma Res. 2013;26(5):634–645. doi: 10.1111/pcmr.12134
- Okada K., Seki M., Yaguchi H. et al. Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature. J. Neurol. 2021;268(2):680–688. doi: 10.1007/s00415-020-10213-x
- Dubey D., David W.S., Amato A.A. et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology. 2019;93(11):e1093–e1103. doi: 10.1212/WNL.0000000000008091
- Kelly Wu W., Broman K.K., Brownie E.R., Kauffmann RM. Ipilimumab- induced Guillain–Barre syndrome presenting as dysautonomia: an unusual presentation of a rare complication of immunotherapy. J. Immunother.2017;40(5):196–199. doi: 10.1097/CJI.0000000000000167
- Тихонова О.А., Дружинин Д.С., Тынтерова А.М., Реверчук И.В. Современное представление о химиоиндуцированной полинейропатии (обзор литературы). Нервно-мышечные болезни. 2023;13(1):10–21. Tikhonova O.A., Druzhinin D.S., Tynterova A.M., Reverchuk I.V. Current understanding of chemotherapy-induced peripheral neuropathy. Neuromuscular Disease. 2023;13(1):10–21. doi: 10.17650/2222-8721-2023-13-1-10-21
- Patel A.S., Snook R.J., Sehdev A. Chronic inflammatory demyelinating polyradiculoneuropathy secondary to immune checkpoint inhibitors in me- lanoma patients. Discov. Med. 2019;28(152):107–111.
- Elkrief A., Derosa L., Zitvogel L. et al. The intimate relationship between gut microbiota and cancer immunotherapy. Gut Microbes. 2019;10(3):424–428. doi: 10.1080/19490976.2018.1527167
- Cappelli L.C., Gutierrez A.K., Bingham C.O. et al. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res. (Hoboken).2017;69(11):1751–1763. doi: 10.1002/acr.23177
- Brahmer J.R., Abu-Sbeih H., Ascierto P.A. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhi- bitor-related adverse events. J. Immunother. Cancer. 2021;9(6). doi: 10.1136/jitc-2021-002435